For this reason, the GINA strategy has suggested oral corticosteroids (OCSs), tiotropium bromide, anti-immunoglobulin E (anti-IgE) monoclonal antibodies, anti-interleukin-5 (anti-IL-5) or its receptor alpha subunit monoclonal antibodies and anti-IL-4 receptor monoclonal antibodies as add-on therapies to try and control symptoms and exacerbations in patients with severe asthma [1]. This evidence concerns the gene IGHE and asthma.